Moderna's (MRNA) COVID-19 Vaccine Nears EUA in Pediatrics

This article was originally published on Nasdaq

Moderna’s MRNA COVID-19 vaccine received the FDA’s Vaccines and Related Biological Products Advisory Committee’s (VRBPAC) vote, backing immunization with two doses as primary vaccination for individuals aged 6 years to 17 years in the United States. The advisory committee

Responses